Nexsen plans to engage with regulators in Australia, the US, and the UK regarding StrepSure to secure approval within the next three years. Image Credit: Number1411 / Shutterstock.

Nexsen Biotech has won A$5.5m ($3.56m) in Australian Federal Government and University support for the clinical development of a rapid point-of-care test, StrepSure.

The grant was part of a consortium consisting of Nexsen, RMIT University and Northern Health in Australia as part of the Cooperative Research Centres Projects (CRC-P) grant process, run by the federal government.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

The A$7.6m StrepSure programme includes A$3m in government funding spread over three years. The funds will support the patient clinical field trials of new low-cost sensor technology in one of the health systems in Victoria, Australia.

RMIT will be responsible for developing a prototype sensor and optimise it through pre-clinical trials. Following this, Nexsen and Northern Heath will conduct validation clinical trials.

Nexsen Biotech plans to engage with regulators in Australia, the US, and the UK, to secure approval within the next three years.

See Also:

Group B streptococcal (GBS) bacteria are commonly found in the rectum and vagina and affects two to four women out of ten, as per the UK National Health Service (NHS). It can cause serious infections in pregnant women, young babies, immunocompromised patients, and the elderly. The bacteria can be treated with antibiotics, but early detection is important to reduce complications.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Current diagnostics to detect GBS include bacterial cultures, which deliver results in one to three days. Nexsen’s point-of-care test is expected to provide results within minutes.

The point-of-care diagnostics market has exploded following the Covid-19 pandemic. Multiple companies have invested in developing point-of-care technologies for detecting infectious disease pathogens. In September 2023, Glasgow-based Microplate Dx raised £2.5m in seed funding to develop a point-of-care device to identify effective antibiotics for bacterial infections.

The Microplate Dx’s device would allow for the confirmation of bacterial presence in the sample and perform rapid antibiotic susceptibility testing to identify the effective antibiotic. It is expected to reduce the analysis time from multiple days to just minutes. The company first plans to develop the device for urinary tract infections (UTIs) and has conducted multiple studies of its UTI prototype.